Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis.

[1]  H. Weiner,et al.  Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis , 1986, Journal of Neuroimmunology.

[2]  C. Brosnan,et al.  IL‐10 fails to abrogate experimental autoimmune encephalomyelitis , 1996, Journal of neuroscience research.

[3]  S. Miller,et al.  Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139‐151 peptide , 1996, Journal of neuroscience research.

[4]  H. Lei,et al.  Intracerebral injection of myelin basic protein (MBP) induces inflammation in brain and causes paraplegia in MBP‐sensitized B6 mice , 1997, Clinical and experimental immunology.

[5]  B. Devaux,et al.  Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide , 1997, Journal of Neuroimmunology.

[6]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[7]  M. Colonna,et al.  Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4 , 2002, Nature Immunology.

[8]  M. Neurath,et al.  Cutting Edge: TGF-β Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells1 , 2004, The Journal of Immunology.

[9]  Shimon Sakaguchi,et al.  IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. , 2004, International immunology.

[10]  L. Steinman,et al.  Multiple sclerosis: trapped in deadly glue , 2005, Nature Medicine.

[11]  Michael Platten,et al.  A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease1 , 2005, The Journal of Immunology.

[12]  Wenlei Jiang,et al.  Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. , 2005, Advanced drug delivery reviews.

[13]  A. Rudensky,et al.  An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires , 2006, Nature Immunology.

[14]  S. Miller,et al.  Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. , 2006, Journal of autoimmunity.

[15]  J. Bluestone,et al.  Regulatory T‐cell physiology and application to treat autoimmunity , 2006, Immunological reviews.

[16]  D. Arnold,et al.  Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. , 2007, Archives of neurology.

[17]  A. Lutterotti,et al.  Antigen-specific therapies in MS — Current concepts and novel approaches , 2008, Journal of the Neurological Sciences.

[18]  B. Liu,et al.  Controlled release of PEI/DNA complexes from PLGA microspheres as a potent delivery system to enhance immune response to HIV vaccine DNA prime/MVA boost regime. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  E. Radue,et al.  Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis , 2008, Annals of neurology.

[20]  U. Dianzani,et al.  CD4+ICOS+ T lymphocytes inhibit T cell activation 'in vitro' and attenuate autoimmune encephalitis 'in vivo'. , 2008, International immunology.

[21]  E. Topp,et al.  Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. , 2008, Journal of pharmaceutical sciences.

[22]  H. Weiner,et al.  Novel CD8+ Treg suppress EAE by TGF‐β‐ and IFN‐γ‐dependent mechanisms , 2009, European journal of immunology.

[23]  J. Tschopp,et al.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[24]  L. Steinman,et al.  Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity , 2010, Journal of internal medicine.

[25]  F. Fallarino,et al.  IDO Upregulates Regulatory T Cells via Tryptophan Catabolite and Suppresses Encephalitogenic T Cell Responses in Experimental Autoimmune Encephalomyelitis , 2010, The Journal of Immunology.

[26]  Yuhong Yang,et al.  TGF-β Enhances Effector Th1 Cell Activation but Promotes Self-Regulation via IL-10 , 2010, The Journal of Immunology.

[27]  H. Swai,et al.  In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[28]  A. Ben-nun,et al.  ‘Multi-Epitope-Targeted’ Immune-Specific Therapy for a Multiple Sclerosis-Like Disease via Engineered Multi-Epitope Protein Is Superior to Peptides , 2011, PloS one.

[29]  L. Faccioli,et al.  The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response. , 2011, International immunopharmacology.

[30]  C. Akdis,et al.  Specific immunotherapy and turning off the T cell: how does it work? , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[31]  W. van Eden,et al.  PLGA, PLGA-TMC and TMC-TPP Nanoparticles Differentially Modulate the Outcome of Nasal Vaccination by Inducing Tolerance or Enhancing Humoral Immunity , 2011, PloS one.

[32]  T. Siahaan,et al.  Immune modulating peptides for the treatment and suppression of multiple sclerosis. , 2012, Clinical immunology.

[33]  R. Spang,et al.  T cells become licensed in the lung to enter the central nervous system , 2012, Nature.

[34]  Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis , 2012, Journal of Neuroinflammation.

[35]  Aaron J. Martin,et al.  Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis , 2012, Nature Biotechnology.

[36]  Krishnendu Roy,et al.  Micro and Nanoparticle‐Based Delivery Systems for Vaccine Immunotherapy: An Immunological and Materials Perspective , 2013, Advanced healthcare materials.

[37]  Alke Fink,et al.  Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes. , 2013, American journal of respiratory cell and molecular biology.

[38]  A. Lutterotti,et al.  Antigen-Specific Tolerance by Autologous Myelin Peptide–Coupled Cells: A Phase 1 Trial in Multiple Sclerosis , 2013, Science Translational Medicine.

[39]  S. Zheng,et al.  Phenotypic and functional characteristic of a newly identified CD8+ Foxp3- CD103+ regulatory T cells. , 2014, Journal of molecular cell biology.

[40]  T. Fahmy,et al.  The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. , 2014, Biomaterials.

[41]  Yuhong Yang,et al.  Treatment of Experimental Autoimmune Encephalomyelitis by Codelivery of Disease Associated Peptide and Dexamethasone in Acetalated Dextran Microparticles , 2014, Molecular pharmaceutics.